Small Pharma Inc.: Difference between revisions
>Chris Created page with "Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom." |
No edit summary |
||
| Line 1: | Line 1: | ||
== Summary == | |||
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom. | Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom. | ||
Revision as of 03:27, 14 August 2022
Summary
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. The company's clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. It is also developing a pipeline of proprietary preclinical assets. The company was founded in 2015 and is headquartered in London, the United Kingdom.